Cornyn, Colleagues Urge SCOTUS to Protect Women & Babies from Dangerous Chemical Abortion Drugs

Cornyn, Colleagues Urge SCOTUS to Protect Women & Babies from Dangerous Chemical Abortion Drugs News Cornyn, Colleagues Urge SCOTUS to Protect Women & Babies from Dangerous Chemical Abortion Drugs May 11, 2026 AUSTIN – U.S. Senator John Cornyn (R-TX) joined more than 100 bicameral Republican lawmakers in filing an amicus brief in the U.S. Supreme Court in support of Louisiana Attorney General Liz Murrill’s lawsuit, Louisiana v. FDA , to protect women and unborn children from dangerous mail-order chemical abortion drugs. This builds on the amicus brief he signed onto earlier this year and comes after the Supreme Court issued a temporary pause of the Fifth Circuit’s order to reinstate the in-person dispensing requirement for mifepristone, which restored access to this dangerous chemical abortion drug nationwide until May 11, 2026. The amicus brief asks the Supreme Court to reconsider their decision and uphold the Fifth Circuit’s ruling to prevent women from obtaining abortion drugs sent through the mail. Excerpts from the amicus brief are below, and the full text of the brief can be viewed here . The lawmakers wrote: “By deregulating chemical abortion drugs and permitting them to be sent through the mail, the Biden FDA violated that longstanding federal law. Unelected, unaccountable bureaucrats in Biden’s FDA therefore overrode the will of the American people as expressed through their elected representatives in Congress and in state legislatures and subverted Congress’s critical public policy interests in upholding patient welfare.” “Further, the Biden FDA’s lawless action also carries serious risks that were not properly analyzed. The Biden FDA did not have a sufficient evidentiary basis to conclude that eliminating the in-person dispensing requirement was safe. And because no in-person visit is required now, women cannot be meaningfully screened for serious contraindications for the use of this drug, such as ectopic pregnancy. It also increases the likelihood that some women are being coerced into taking these drugs against their will,” they continued. “As delegated by Congress, the FDA’s job is to ensure drug safety, not to encourage the risky use of drugs just to further former President Biden’s pro-abortion agenda. Exceeding its mandate is illegal and also harmful, both to the separation of powers and to women taking mifepristone. The Fifth Circuit was correct to grant a stay and the Court should deny the applications to stay that judgment,” they concluded.